Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

Also called NCT04734548

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 151 participants (enrolled count) (from the registry)
Sponsor
aptaTargets S.L. (from the registry)
Registry
  • NCT NCT04734548
Other papers using this trial's data
  • Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial JAMA neurology, 2023-08-01 DOI, PubMed 37338893, PMC10282959 PubMed links an erratum for this paper. Erratum: PMID 38407880 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France, Germany, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04734548. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-28 (actual); primary completion 2022-07-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke
Condition
Stroke
Condition
Acute Stroke
Intervention (Drug)
ApTOLL
Intervention (Other)
Placebo
Lead sponsor
aptaTargets S.L. (class: industry)
Collaborator
Ministry of Science and Innovation, Spain (class: other government)
Collaborator
Anagram (class: not stated)

Record details

Record id
cardio:ct-nct04734548
Content hash
407cc6a5c83200a62b7412d733e12ab96c733910a5f2830ef54b07b70d07e5b8